Table 2 Clinical response to chemotherapy

From: A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Response

Group 1 TE N (%)

Group 2 TEL N (%)

CR

20 (31.7)

29 (46.8)

PR

26 (41.3)

29 (46.8)

SD

14 (22.2)

3 (4.8)

PD

2 (3.2)

0 (0)

Total

63 (100)

62 (100)

  1. TE docetaxel and epirubicin, TEL docetaxel, epirubicin, and lobaplatin, CR complete response, PR partial response, SD stable disease, PD progression of disease
Back to article page